To analyze the effect of a splenectomy on pancytopenia after a peripheral blood stem cell transplantation (PBSCT) in chronic myeloid leukemia (CML) patients. Three CML patients diagnosed with splenomegaly in our department from 2002 to 2006 received a splenectomy after PBSCT. Patient 1, a 42-year-old male in chronic phase (CP), received an HLA-identical sibling allo-PBSCT. Patient 2, a 28-year-old female in aggressive phase (AP), received a PBSCT from her twin. Patient 3, a 26-year-old male in chronic phase (CP), received a PBSCT from an unrelated donor. The conditioning regimen included busulfan and cyclophosphamide (BU/CY2). Patients 1, 2, and 3 received splenectomies on days 168, 51, and 114, respectively. Bcrabl transcripts were detected using the polymerase chain reaction (PCR). Chimerism was documented by PCR amplification of a variable number of tandem repeat (VNTR) polymorphrisms. Neither metrisone (2 mg/kg/day for 7 days), mycophenolic acid (MMF) (0.5 g twice daily for 1 month), high-dose γ-globulin (0.4 g/kg/day for 5 days), granulocyte colony-stimulating factor (G-CSF) therapy, nor erythropoietin (EPO) therapy had produced post-PBSCT hematopoiesis recovery. Patients 1 and 2 had 5% Ph-positive chromosomes while patient 3 exhibited graft-versus-host disease (GVHD). After receiving the splenectomy, all three had a rapid hematopoeitic recovery with no evidence of Ph-positive chromosomes, and patients 1 and 3 showed complete donor chimerism (CDC). Patient 1 developed chronic GVHD (cGVHD) on day 210 postsplenectomy that was treated successfully with prednisone. Patient 2 had acute GVHD on day 55 that was treated successfully with dexamethasone (10 mg), administered intravenously once a day for 3 days with good clinical response. To date, patients 1, 2, and 3 have survived postprocedure for 85, 49, and 25 months, respectively. Splenectomy is an effective option for the patients who have pancytopenia after PBSCT and the patients recovered a good graft function after splenectomy without procedure-related complication and with long-time survival. GVHD can develop in both allo-PBSCT and syngeneic PBSCT. A splenectomy after PBSCT may increase the risk of GVHD, enhance the effect of graft versus leukemia (GVL), promote CDC formation.
INTRODUCTION
Recently, many studies have assessed the role of the spleen in peripheral blood stem cell transplantation (PBSCT). A splenectomy performed before an allogenic Hematopoietic stem cell transplantation (HSCT) is an established treatment for patients with several disorders PBSCT (allo-PBSCT) for the treatment of chronic myelogenous leukemia (CML) has been controversial. Ba-including life-threatening hematological diseases, immune deficiencies, and genetic metabolic disorders (1, 8) .
naji et al. have reported a faster neutrophil and platelet recovery and decreased platelet transfusion requirements Despite advances in prevention and posttransplant immunosuppressive strategies, graft-versus-host disease when a splenectomy is performed prior to transplantation (2) . In addition, Michallet et al. concluded that a (GVHD) continues to be a major life-threatening complication after allogeneic bone marrow transplantation splenectomy was the most important factor in predicting GVHD severity, since one possible function of the (11,13). Many factors influence GVHD, such as the duration of time between diagnosis and transplantation, spleen is to filter activated T lymphocytes arising from the transplant (14). One study suggested that a spleno-disease status at transplantation, conditioning regimen, marrow cell doses, and the donor-recipient ABO blood megaly is a poor prognostic feature in patients with CML undergoing a related donor marrow transplant (7) . match (6) . In contrast, two studies have reported that a splenectomy positive cells in all metaphases analyzed. The patient received hydrea and IFN therapy, which effectively con-performed prior to an allo-PBSCT had no influence on the occurrence of GVHD (3, 5) . The effect of a splenec-trolled the WBC count prior to PBSCT. Patient 3 was a 26-year-old man who presented with tomy on graft function performed after a PBSCT has rarely been reported. Richard et al. reported that four fatigue in 2006. Clinically, his spleen was enlarged 12 cm below the left costal margin. Full blood examination patients diagnosed with CML that had poor graft function after receiving a non-T-cell-depleted bone marrow revealed hemoglobin 110 g/L, a WBC count of 380.4 × 10 9 /L, and a platelet count of 587 × 10 9 /L. Bone marrow transplantation from an HLA-compatible sibling donor were successfully treated by a splenectomy (16) . The examination morphologically resembled chronic phase CML. Cellularity was markedly increased with an M/E study conclusions showed that CML patients with poor graft function could be successfully treated with a sple-ratio of 244:1. The differential was as follows: neutrophils 92%, eosinophils 2%, metamyelocytes 12%, mye-nectomy. However, the effect of a splenectomy on GVHD performed after a PBSCT, analysis of complete locytes 9%, promyelocytes 1%, myeloblasts 0%, basophils 3%, lymphocytes 2%, and erythroblasts 0.4%. donor chimerism (CDC) formation, and disease relapse have not been reported.
Bone marrow cytogenetics revealed Ph-positive cells in all metaphases analyzed. The patient received hydrea In this study, we analyzed the effect of a splenectomy performed after an allo-PBSCT and syngeneic PBSCT and IFN therapy, which effectively controlled the WBC count prior to PBSCT. on GVHD and the formation of CDC in three CML patients from our clinical department between CML were used in this study. The busulfan and cyclophosphamide (BU-CY2) conditioning regimen consisted history. Clinically, his spleen was enlarged 17 cm below the left costal margin. Full blood examination revealed of busulfan (1 mg/kg) administered every 6 h for 16 days and cyclophosphamide (CTX) (60 mg/kg) adminis-hemoglobin 112 g/L, a white blood cell (WBC) count of 213 × 10 9 /L, and a platelet count of 543 × 10 9 /L. Bone tered once a day for 2 days. Each donor received granulocyte colony-stimulating factor (G-CSF) (300 µg) once marrow examination morphologically resembled chronic phase CML. Cellularity was markedly increased with an a day for 6 days for mobilization. A median of 12 L (3 times the total blood volume) of donor blood was pro-M/E ratio of 18:1. The differential was as follows: neutrophils 83%, eosinophils 4%, metamyelocytes 8%, my-cessed and collected. Each recipient received 8 × 10 6 CD34 + cells/kg of body weight. All patients and their elocytes 12%, promyelocytes 4%, myeloblasts 1%, basophils 2%, lymphocytes 1%, and erythroblasts 5%.
donors gave written informed consent, and this study was approved by Institutional Review Board and the Bone marrow cytogenetics revealed Ph-positive cells in all metaphases analyzed. The patient received hydrea Ethics Committee at Southeast University. and interferon (IFN) therapy, which effectively con-GVHD Prophylaxis trolled the WBC count prior to PBSCT.
Patient 2 was a 28-year-old woman who presented Cyclosporin A (CsA) and methotrexate (MTX) were administered as a GVHD prophylaxis treatment. The with fatigue in 2003. Her spleen was enlarged 4 cm below the left costal margin. Full blood examination re-regimen consisted of 3 mg/kg of intravenous CsA with a target blood level of 200-400 ng/L and a short course vealed hemoglobin 108 g/L, a WBC count of 67.7 × 10 9 / L, and a platelet count of 539 × 10 9 /L. Bone marrow treatment of MTX (15 mg on day 1 and 10 mg on days 3, 6, and 11, respectively). A full dose of CsA was ad-examination morphologically resembled chronic phase CML. After 2 years, bone marrow examination showed ministered through day 50. If GVHD was successfully treated at that point, the dose was gradually reduced, that cellularity was markedly increased with an M/E ratio of 19:1. The differential was as follows: neutrophils and ended on the sixth month. Anti-thymocyte globulin (ATG) was administered for 3 days at a dose of 1000 62%, eosinophils 6%, metamyelocytes 8%, myelocytes 12%, promyelocytes 14%, myeloblasts 6%, basophils mg for the unrelated donor of patient 3. Chronic GVHD (cGVHD) was diagnosed if the disease occurred in pa-6%, lymphocytes 1%, and erythroblasts 5%. Bone marrow examination morphologically resembled accelerated tients that survived for more than 100 days posttransplantation. The diagnosis of acute and chronic GVHD phase CML. Bone marrow cytogenetics revealed Ph-was based on classic clinical and biological criteria and marrow specimens showed that the Ph-positive cells decreased to 5%. Chromosome analysis of bone marrow was confirmed by histological examination whenever possible.
cells each month showed mixed donor chimerism.
Pancytopenia. After day 90, the patient's hemoglo-Cytomeglovirus and Hepatic Vein Occlusion bin decreased gradually to a level of 60 g/L with the Disease Prophylaxis platelet count and WBC count being 19 × 10 9 /L and 1.8 × Intravenous ganciclovir (5 mg/kg) was administered 10 9 /L, respectively ( Fig. 1 ). Metrisone (2 mg/kg) was every day from 8 days prior to the procedure to 5 days administered each day for 7 days without an effect. Myafter the procedure. Cytomegalovirus DNA (CMVcophenolic acid (MMF) (0.5 g) was administered twice DNA) was monitored by PCR once a week. Prostaglaneach day for 1 month without any indication of hematodin E 1 (PGE 1 ) (20 µg) was administered prophylactically poiesis recovery. Subsequently, a high-dose of γ-globuand intravenously once a day for 2 days for hepatic vein lin (0.4 g/kg) was administered once a day for 5 days occlusion disease (VOD) starting 8 days prior to the prowith no effect. G-CSF (150 µg) was given once per day cedure and continuing 28 days postprocedure.
subcutaneously and erythropoietin (EPO) (10,000 units) was administered three times a week without clear bene-Engraftment fits. The patient exhibited an increase in WBC count The neutrophil engraftment start point was defined as without any improvement in hemoglobin level or platethe first day of 3 consecutive days when the absolute let count. neutrophil count (ANC) exceeded 0.5 × 10 9 /L. The Splenectomy and Hematopoietic Recovery. An abplatelet engraftment start point was defined as the first dominal ultrasound of patient 1 showed an enlarged day of 5 consecutive days when the platelet count exspleen (22 × 16 × 6 cm) and the patient received a spleceeded 50 × 10 9 /L independently without a platelet nectomy on day 168. Pathological analysis of the spleen transfusion. Engraftment was evaluated by blood cell revealed hypersplenism. Prophylactic platelet transfucounts, bone marrow (BM) examination, and cytogesion was administered before the splenectomy. Hematonetic and molecular analysis.
logical recovery occurred quickly after the splenectomy and a level of hemoglobin greater than 10 g/L was Supportive Care reached within 24 h of the procedure. Pathological anal-Patients were cared for in single rooms equipped with ysis of the resected spleen confirmed hypersplenism. a high-efficiency particle air filtration system until Histological examination of the spleen showed splenic reaching neutrophil recovery. Trimethoprim-sulfamethwhite pulp disappear, trabecular thinning, medullary oxazole was administered immediately in cases of neucord widened, sinusoidal hyperplasia with large numbers tropenic fever. Itraconazole was given for suspected funof neutrophils including some immature forms. Metamygal infections. Patients were transfused with irradiated elocytes and promyelocytes and late erythroblast are blood products to maintain their hemoglobin level above also scattered visible. Cytogenetic studies of bone mar-8.0 g/dl and platelet count above 20 × 10 9 /L. Daily Grow samples 2 months after the transplantation showed CSF was administered intravenously starting on the fifth no Ph-positive cells. Chromosome analysis of bone marday after the allo-PBSCT and continued until the ANC row cells after the splenectomy showed complete donor was greater than 0.5 × 10 9 /L for 3 consecutive days.
chimerism.
RESULTS
GVHD. The patient had no signs of acute GVHD. On day 210, the patient developed cGVHD that was lim-Clinical details of the three patients included in this ited to the skin after the splenectomy. Administration of study are provided in Table 1 .
a high dose of CsA and prednisone resulted in a good Patient 1 clinical response.
Engraftment. Patient 1 received a sustained myeloid
Patient 2 and platelet engraftment on day 15 and had a WBC count of 1.2 × 10 9 /L, an ANC of 0.9 × 10 9 /L, and a platelet Engraftment. On day 15, patient 2 had a WBC count of 1.8 × 10 9 /L, ANC of 0.5 × 10 9 /L, and platelet count count greater than 20 × 10 9 /L at day 46. The hemoglobin level increased to 86 g/L after transplantation. Bone mar-of 15 × 10 9 /L. Bone marrow examination 1 month after the transplantation revealed low cell proliferation with row examination 1 month after transplantation revealed obvious proliferation with a granulocytic and erythrocytic granulocytic and erythrocytic percentages of 34% and 47%, respectively. Cytogenetic analysis of bone marrow percentage of 62% and 26.4%, respectively. No increase in erythroblasts was detected. Cytogenetic studies on bone samples showed that the Ph-positive cells decreased to 5%. Pancytopenia and Delayed Bone Marrow Recovery. fusion, the WBC count and ANC were 3.0 × 10 9 /L and 2.2 × 10 9 /L, respectively. A second bone marrow exami-On day 18, the platelet count decreased to 5 × 10 9 /L. The WBC count and ANC were 1.7 × 10 9 /L and 1.1 × nation after the transplantation revealed a higher cell proliferation with granulocytic and erythrocytic percent-10 9 /L, respectively. A platelet transfusion on day 46 increased the platelet count to 11 × 10 9 /L. After the trans-ages of 70.4% and 24.8%, respectively. 
Splenectomy and Hematopoitic
Recovery. An ab-showed no Ph-positive cells. Chromosome analysis of bone marrow cells each month showed complete donor dominal ultrasound showed an enlarged spleen (14 × 8 × 6 cm) in patient 2. Considering the possibility of hyper-chimerism. splenism and a delay in the recovery of bone marrow, Pancytopenia. Patient 3 was treated with G-CSF and the patient received a splenectomy on day 51 (Fig. 2) .
achieved a maximal unsustained WBC count of 8.2 × The platelet count increased quickly to 20 × 10 9 /L after 10 9 /L that decreased to 1.1 × 10 9 /L after treatment withthe splenectomy and the WBC count and hemoglobin drawal (Fig. 3) . The patient was transfusion dependent level were 20.2 × 10 9 /L and 112 g/L, respectively. Bone after the transplantation. The range of hemoglobin levels marrow examination 1 month after the splenectomy reand platelet counts were 50-65 g/L and 17-33 × 10 9 /L, vealed cell proliferation with granulocytic and erythrorespectively. cytic percentages of 56% and 33.2%, respectively. Two Splenectomy and Hematopoietic Recovery. An abmegakaryocytes were also observed. Pathological analydominal ultrasound showed an enlarged spleen (21 × sis of the resected spleen confirmed hypersplenism. His-14.5 × 4 cm) in the patient. On day 114, the patient retological examination of the spleen showed splenic ceived a splenenctomy. Spleen pathology revealed hywhite pulp shrink, the medullary cord and sinus of red persplenism. Three days after the splenectomy, the pulp with large numbers of neutrophils. Some immature WBC count, hemoglobin level, and platelet count were forms and late erythroblast are scattered visible. A mild 6.3 × 10 9 /L, 10 8 g/L, and 53 × 10 9 /L, respectively. Pathored pulp congestion was also observed. Cytogenetic logical analysis of the resected spleen confirmed hyperanalysis of the bone marrow samples performed 2 months splenism. This patient's spleen showed sinusoidal hyafter the transplantation showed no Ph-positive cells.
perplasia with large numbers of neutrophils including GVHD. On day 55, patient 2 presented with erythra some immature forms, but the spleen showed no other on her body. To determine the possibility of syngeneic abnormality. Bone marrow examination performed 1 GVHD (sGVHD), we performed a left clavicle skin bimonth after the splenectomy revealed proliferation with opsy. Pathological analysis of the skin biopsy confirmed granulocytic and erythroblast percentages of 62% and sGVHD. Dexamethasone (10 mg) was administered 32%, respectively. Four megakaryocytes were also obonce a day for 3 days and resulted in a good clinical served. Cytogenetic studies performed 2 months after response.
the transplantation on bone marrow samples showed no Ph-positive cells. Chromosome analysis of bone marrow Patient 3 cells after the splenectomy showed complete donor chi-Engraftment. On day 12, patient 3 had a WBC count merism. of 0.8 × 10 9 /L, ANC of 0.6 × 10 9 /L, and platelet count of 17 × 10 9 /L. Bone marrow examination 1 month after GVHD. Patient 3 presented with a rash on the upper and lower limbs on day 10. The patient received immu-the transplantation revealed obvious proliferation with granulocytic and erythrocytic percentages of 53% and nosuppressive treatment for GVHD at the time of diagnosis. Administration of dexamethasone (10 mg/day for 42%, respectively. Two megakaryocytes were also observed. Cytogenetic analysis of bone marrow samples 7 days) resulted in a good clinical outcome. On day 72, the patient presented with a rash on both palms and feet male donor to male recipient, relative response and donor-responding capacity in mixed lymphocyte culture and had diarrhea. Additional treatment with dexamethasone (5 mg) and high-dose intravenous γ-globulin (MLC), and MNS blood group antigen, and concluded that a splenectomy was not associated with acute GVHD cleared the rash and diarrhea after 15 days.
(10). Another study has shown no significant influence of a splenectomy on acute GVHD, cGVHD, or overall DISCUSSION patient survival (12). However, other studies have indicated that the spleen may modulate the severity and inci-Pancytopenia that occurs after PBSCT is associated with GVHD, graft failure, myelofibrosis, viral infection, dence of acute GVHD (19). One explanation for this could be the possible function of the spleen as a filter the need for administration of drugs, and autoimmune diseases. In this study, we have analyzed the effect of a of activated T lymphocytes arising from the transplant (14). Chronic GVHD is also associated with hyposplen-splenectomy on pancytopenia. In all cases, the patients had enlarged spleens but no evidence of cytomegalovi-ism (4, 17) . In one study, a 39-year-old female patient underwent HLA-identical sibling allogeneic BMT for rus infection or severe acute GVHD at the time of the splenectomy. Severe pancytopenia refractory to G-CSF-the treatment of CML in the accelerated phase. A splenectomy was performed on day 225 and the pancyto-associated and red blood cell (RBC)/platelet transfusion dependency was present after the bone marrow trans-penia was resolved; however, extensive cGVHD developed with associated hepatic cholestasis, diffuse plant (BMT). After surgery, all patients were transfusion independent and had sustained graft function with nor-scleroderma, and sicca-like syndrome. The authors concluded that hyposplenism may trigger or aggravate ex-mal peripheral hematological parameters. It has been previously reported that four CML patients that showed tensive cGVHD and could lead to increased morbidity and mortality (18) . In the current study, patients 1 and poor graft function after BMT from an HLA-compatible sibling donor were successfully treated by a splenec-2 had no evidence of GVHD before the splenectomy was performed. However, both patients developed tomy (11). These data suggest that a poor graft function may be successfully corrected by a splenectomy. Hyper-GVHD immediately after the splenectomy. Subsequently, after treatment all of the patients have remained splenism should be considered in patients that present persistent or recurrent pancytopenia and splenomegaly disease free. The effect of a splenectomy performed post-PBSCT posttransplantation (9). Others believe a splenectomy should be considered prior to a transplant in patients on the formation of CDC has not previously been reported. In the current study, the chimerism of bone mar-with significant splenomegaly and hypersplenism (15).
Although the role of the spleen in GVHD is contro-row from patient 1 before the splenectomy was mixed donor chimerism but changed to CDC immediately after versial, it is considered to be a crucial secondary lymphoid organ in acute GVHD when the disease is initiated the splenectomy. Patient 2 had syngeneic PBSCT and therefore we could not test the chimerism of the bone by donor T cells that recognize host alloantigens after an allo-BMT (5) . Hägglund et al. analyzed 35 risk fac-marrow samples. Patient 3 received an allogeneic PBSCT from an unrelated donor and we observed acute tors in acute GVHD, such as age, time of diagnosis, fe-
